<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154535">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675791</url>
  </required_header>
  <id_info>
    <org_study_id>TT-02</org_study_id>
    <nct_id>NCT01675791</nct_id>
  </id_info>
  <brief_title>A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet</brief_title>
  <official_title>A Dose-response Evaluation of ALK Tree AIT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Lithuania: State Medicines Control Agency</authority>
    <authority>The Netherlands: Medicines Evaluation Board</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this trial is to evaluate the dose-response relationship for the ALK tree
      AIT administered once daily in order to define a dose-range that would be suitable for
      at-home administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Allergy symptom severity scores on a scale from 0-3</measure>
    <time_frame>During the birch pollen season 2013, an expected average of 3 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine the dose-efficacy response relationship of the ALK tree AIT. This information will, in combination with the evaluation of the frequency and severity of adverse events, form the basis of the conclusion on the primary endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events frequency</measure>
    <time_frame>Throughout the trial, an expected average of 8 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the dose-safety response relationship of the ALK tree AIT. This information will, in combination with the evaluation of the allergy symptoms, form the basis of the conclusion on the primary endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events severity</measure>
    <time_frame>Throughout the trial, an expected average of 8 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the dose-safety response relationship of the ALK tree AIT. This information will, in combination with the evaluation of the allergy symptoms, form the basis of the conclusion on the primary endpoint.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">637</enrollment>
  <condition>Birch Pollen Allergy</condition>
  <arm_group>
    <arm_group_label>ALK tree AIT Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 AIT administered sublingually every day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK tree AIT 0.5 DU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 AIT administered sublingually every day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK tree AIT 1 DU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 AIT administered sublingually every day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK tree AIT 2 DU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 AIT administered sublingually every day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK tree AIT 4 DU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 AIT administered sublingually every day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK tree AIT 7 DU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 AIT administered sublingually every day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK tree AIT 12 DU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 AIT administered sublingually every day</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALK tree AIT 0.5 DU</intervention_name>
    <arm_group_label>ALK tree AIT 0.5 DU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALK tree AIT 1 DU</intervention_name>
    <arm_group_label>ALK tree AIT 1 DU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALK tree AIT 2 DU</intervention_name>
    <arm_group_label>ALK tree AIT 2 DU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALK tree AIT 4 DU</intervention_name>
    <arm_group_label>ALK tree AIT 4 DU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALK tree AIT 7 DU</intervention_name>
    <arm_group_label>ALK tree AIT 7 DU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALK tree AIT 12 DU</intervention_name>
    <arm_group_label>ALK tree AIT 12 DU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALK tree AIT Placebo</intervention_name>
    <arm_group_label>ALK tree AIT Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A history of moderate to severe birch pollen allergy

          -  Use of symptomatic medication for treatment of birch pollen allergy

          -  Positive skin prick test to birch extract

          -  Positive specific IgE against Bet v 1

        Exclusion Criteria:

          -  Overlapping perennial allergies

          -  History of uncontrolled asthma within the last 3 months

          -  FEV1 &lt; 70% of predicted value in adults or FEV1 &lt; 80% of predicted value in
             adolescents

          -  Previous or ongoing treatment with immunotherapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Skin and Allergy Hospital, Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <state>HUS</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaart Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>August 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
